In our study, mean age of serous carcinoma patients at the time of diagnosis was found to be 47.2 years while it was 43.1 years for mucinous carcinoma, 47.5 years for endometrioid carcinoma
, 26.8 years for germ cell (malignant) tumour and 45.4 years for sex-cord stromal (malignant) tumour.
* There was complete PTEN loss (Negative immunoreactivity) in 37% cases of endometrial hyperplasia with atypia and 61% cases of endometrioid carcinoma
Overall, endometrioid carcinomas
were the most common uterine cancers (68%).
Most frequent type was serous carcinoma (SC) followed by mucinous carcinoma (MC) and endometrioid carcinoma
In grade III there were 12 cases out of which 3 cases were of Serous carcinoma, one case of Clear cell carcinoma, two cases of Carcinonosarcoma and six cases of Endometrioid carcinoma
. ER positive 11 (19.6%) tumours were in grade I, ER positive grade II tumors were 9(16.9%) whereas in grade III tumors, ER positive were 5(8.9%)(Table-I).
Normal endometrial stroma and glands usually stain negative or weak while endometrioid carcinoma
stained stronger (Figure 4(c)).
Atypical polypoid adenomyoma mixed with endometrioid carcinoma
: A case report.
Dilatation and curettage under hysteroscopy were performed in 6 patients before surgery, and pathology revealed 2 cases of endometrioid carcinoma
, 3 cases of endometrial atypical hyperplasia not exclusive of carcinoma, and 1 case of complex hyperplasia.
Call-Exner-like areas can be seen in other tumours such as endometrioid carcinoma
of the ovary, but in this case the tumour may contain mucin, which is not a feature of GCTs.
The uterine lesion was a FIGO grade 3 endometrioid carcinoma
. The tumour had extended into the outer myometrium but was clear by 2.5 mm.
There are two clinicopathological variants: the estrogen-related, type I, endometrioid carcinoma
, and the nonestrogen-related, type II, nonendometrioid carcinoma .
Type 1 is estrogen-related endometrioid carcinoma
divided into subtypes, adenocarcinomas with squamous differentiation further subdivided into adenocarcinoma with squamous metaplasia (adenoacanthoma) and adenosquamous carcinoma, secretory, ciliated cell, and villoglandular variants .